Skip to main content
CMEducation Resources ScrollCall
  • menu
  • menu
  • person
  • Search
  • Specialty
  • Cardiology chevron_right

  • Specialty Program
  • Hypothyroidism chevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • Diabetes chevron_right

  • Specialty Program
  • Glycemic Regulation chevron_right
  • Hypothyroidism chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • Specialty Program
  • Congenital Adrenal Hyperplasia (CAH) chevron_right
  • Cytokine Immunotherapy chevron_right
  • Hypothyroidism chevron_right
  • Specialty Program
  • Parkinson's Diseasechevron_right
  • Specialty
  • Prenatal Screening chevron_right

  • Specialty Program
  • Prenatal Screening chevron_right
  • Specialty
  • Cancer chevron_right

  • Specialty Program
  • Cytokine Immunotherapy chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Pain Management chevron_right
  • Specialty
  • Primary Care chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Congenital Adrenal Hyperplasia (CAH) chevron_right
  • Hypothyroidism chevron_right
  • Pain Management chevron_right
  • Parkinson's Diseasechevron_right
  • Glycemic Regulation chevron_right
  • Specialty
  • Dermatology chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Cytokine Immunotherapy chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Specialty
  • Biologicschevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Biosimilars for RA chevron_right
  • Cytokine Immunotherapy chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • MAC Lung Disease chevron_right

  • Specialty Program
  • MAC Lung Disease chevron_right
    • close
    CMEducation Resources iQ&A
    • person
    • Home
    • Access All Programs
    • Specialtieschevron_right
      • chevron_leftTopics
      • Cardiology
      • Diabetes
      • Endocrinology
      • Neurology
      • Cancer
      • Primary Care
      • Dermatology
      • Biologics
      • MAC Lung Disease
    • Submit A Question
    close

    Antonio Catanzaro, MD

    Antonio Catanzaro, MD

    Professor of Medicine
    Previously, Director, Tuberculosis Control
    Division of Pulmonary, Critical Care, and Sleep Medicine
    UC San Diego School of Medicine
    San Diego, California


    Related Videos

    What clinical, microbiological, and radiographic triggers do you need in an individual with MAC lung infection to embark on anti-infective treatment? How often do you see patients with NTM disease and how do you make the decision to treat or monitor? Video

    What clinical, microbiological, and radiographic triggers do you need in an individual with MAC lung infection to embark on anti-infective treatment? How often do you see patients with NTM disease and how do you make the decision to treat or monitor?

    What data and experience have been accumulated over time that explain why NTM pulmonary infection has now become recognized as a significant disease problem with a formidable disease burden and unmet therapeutic needs? Video

    What data and experience have been accumulated over time that explain why NTM pulmonary infection has now become recognized as a significant disease problem with a formidable disease burden and unmet therapeutic needs?

    Given the complex clinical decision tree for NTM lung disease, what is your best counsel for how to optimize clinical outcomes across the severity range for this increasingly recognized pulmonary infection? Video

    Given the complex clinical decision tree for NTM lung disease, what is your best counsel for how to optimize clinical outcomes across the severity range for this increasingly recognized pulmonary infection?

    Can you summarize your perspective on advances in the treatment of MAC lung disease and your position on amikacin liposome inhalation suspension in patients who require intensification beyond three-drug oral treatment? Video

    Can you summarize your perspective on advances in the treatment of MAC lung disease and your position on amikacin liposome inhalation suspension in patients who require intensification beyond three-drug oral treatment?

    When does the accumulated clinical data—i.e. cavitation, symptom severity, etc.—support the use for amikacin, either systemically or with the inhaled liposome suspension, for MAC lung disease? Video

    When does the accumulated clinical data—i.e. cavitation, symptom severity, etc.—support the use for amikacin, either systemically or with the inhaled liposome suspension, for MAC lung disease?

    How do you navigate the multiple branch points of guideline-endorsed therapy for MAC lung function? And how do you make modifications in dosing frequency, and in what patients do you consider such changes? Video

    How do you navigate the multiple branch points of guideline-endorsed therapy for MAC lung function? And how do you make modifications in dosing frequency, and in what patients do you consider such changes?

    How long should treatment be continued with three-drug oral therapy before the regimen is considered to be successful or whether lack of culture conversion suggests intensification with amikacin is indicated? Video

    How long should treatment be continued with three-drug oral therapy before the regimen is considered to be successful or whether lack of culture conversion suggests intensification with amikacin is indicated?

    Given the tolerability issues associated with the currently applicable—although last issued in 2007—treatment guidelines for NTM lung disease, how do you sequence and titrate therapy in patients you commit to anti-infective treatment? Video

    Given the tolerability issues associated with the currently applicable—although last issued in 2007—treatment guidelines for NTM lung disease, how do you sequence and titrate therapy in patients you commit to anti-infective treatment?

    Can you take us through microbiological testing for NTM and MAC lung disease, emphasizing the specific tests required to confirm diagnosis and specific causative pathogens; and when such testing should be continued throughout treatment? Video

    Can you take us through microbiological testing for NTM and MAC lung disease, emphasizing the specific tests required to confirm diagnosis and specific causative pathogens; and when such testing should be continued throughout treatment?

    Disclaimer:
    Copyright © by CMEducation Resources, LLC All rights reserved. Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
    Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
    Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
    Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

    Clinical Webcasts®

    Powered by BroadcastMedBROADCASTMED